Patent US4547509A successfully refreshed from Google Patents.
US4547509A
Expired / Lapsed
US
⏱️ 0.0 years remaining
5,6,7-Quinoline carbanilates and method of treating ischemic heart disease therewith
Assignee: USV Pharmaceutical Corp
•
Filing: 1983-01-03
•
Granted: 1985-10-15
•
Expires: 2003-01-03
Abstract
Abstract Compounds of the structure ##STR1## and pharmaceutically acceptable salts thereof wherein: R 1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, acylamino, dialkyl amino, trihalomethyl, halogen, nitro, hydroxy or cyano; X is in the 5, 6 or 7 position and is O(CH 2 ) n , N(CH 2 ) n --R 3 , S(CH 2 ) n or (CH 2 ) n ; Y is O(CH 2 ) n , S(CH 2 ) n , N(CH 2 ) n --R 3 where R 3 is H, alkyl or (CH 2 ) n ; R 2 is monosubstituted or independently disubstituted H, hydroxy, alkyl, halogen, nitro, alkoxy, carboxyl, alkylcarboxy, trihalomethyl, cyano, trifluoromethyl, dialkylamino or acylamino; Z is O, S or (NR 3 ) 2 where R 3 is H, alkyl or aryl; and n is 0 to 10 inclusive useful in the treatment of ischemic heart disease and hypertriglyceridemia.
Inventors
- 👤 John H. Musser
- 👤 Charles A. Sutherland
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 05:33
CPC Classifications
C; C07; C07D; C07D215/00; C07D215/02; C07D215/16; C07D215/20; A; A61; A61P; A61P3/00; A61P3/06; C07D215/12; C07D215/14
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
100 words
A compound of the structure: ##STR6## and pharmaceutically acceptable salts thereof wherein: R 1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, lower alkyl carbonyl amido, dialkyl amino, trichloromethyl, tribromomethyl, trifluoromethyl, halogen, nitro, hydroxy or cyano: X is in the 5, 6 or 7 position and is O Y is N-R 3 where R 3 is H or alkyl; R 2 is H, monosubstituted or disubstituted hydroxy, alkyl, halogen, nitro, alkoxy, carboxyl, alkylcarboxy, trichloromethyl, tribromomethyl, trifluoromethyl, cyano, dialkylamino or lower alkyl carbonyl amido; wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy contain from 1 to 7 carbon atoms.
Claim 2
Dependent Claim
100 words
A compound of the structure: ##STR6## and pharmaceutically acceptable salts thereof wherein: R 1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, lower alkyl carbonyl amido, dialkyl amino, trichloromethyl, tribromomethyl, trifluoromethyl, halogen, nitro, hydroxy or cyano: X is in the 5, 6 or 7 position and is O Y is N-R 3 where R 3 is H or alkyl; R 2 is H, monosubstituted or disubstituted hydroxy, alkyl, halogen, nitro, alkoxy, carboxyl, alkylcarboxy, trichloromethyl, tribromomethyl, trifluoromethyl, cyano, dialkylamino or lower alkyl carbonyl amido; wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy contain from 1 to 7 carbon atoms.
Claim 3
Dependent Claim
18 words
The compound of claim 1 wherein said alkyl group and the alkyl moieties in alkoxy are straight chains.
Claim 4
Dependent Claim
20 words
The compound of claim 1 wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy are branched chains.
Claim 5
Dependent Claim
39 words
The compound of claim 1 wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy are selected from the group consisting of methyl, ethyl, normal- propyl, isopropyl, normal-butyl, isobutyl, secondary- and tertiary-butyl, normal-amyl, isoamyl, secondary- and tertiary-amyl.
Claim 6
Dependent Claim
128 words
A therapeutic composition for inhibiting lipolysis in a mammal which comprises, in combination with at least one pharmaceutically-acceptable extender, an effective amount for the inhibition of lipolysis of a compound of the formula: ##STR7## and pharmaceutically acceptable salts thereof wherein: R 1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, lower alkyl carbonyl amido, dialkyl amino, trichloromethyl, tribromomethyl, trifluoromethyl, halogen, nitro, hydroxy or cyano; X is in the 5, 6 or 7 position and is 0, Y is N--R 3 where R 3 is H or alkyl; R 2 is monosubstituted or disubstituted H, hydroxy, alkyl, halogen, nitro, alkoxy, carboxyl, alkylcarboxy, trichloromethyl, tribromomethyl, trifluoromethyl, cyano, dialkylamino or lower alkyl carbonyl amido; wherein said alkyl groups and the alkyl moieties in alkoxy and alkylcarboxy contain from 1 to 7 carbon atoms.
Claim 7
Dependent Claim
128 words
A therapeutic composition for inhibiting lipolysis in a mammal which comprises, in combination with at least one pharmaceutically-acceptable extender, an effective amount for the inhibition of lipolysis of a compound of the formula: ##STR7## and pharmaceutically acceptable salts thereof wherein: R 1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, lower alkyl carbonyl amido, dialkyl amino, trichloromethyl, tribromomethyl, trifluoromethyl, halogen, nitro, hydroxy or cyano; X is in the 5, 6 or 7 position and is 0, Y is N--R 3 where R 3 is H or alkyl; R 2 is monosubstituted or disubstituted H, hydroxy, alkyl, halogen, nitro, alkoxy, carboxyl, alkylcarboxy, trichloromethyl, tribromomethyl, trifluoromethyl, cyano, dialkylamino or lower alkyl carbonyl amido; wherein said alkyl groups and the alkyl moieties in alkoxy and alkylcarboxy contain from 1 to 7 carbon atoms.
Claim 8
Dependent Claim
21 words
The therapeutic composition of claim 5 wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy are straight chains.
Claim 9
Dependent Claim
21 words
The therapeutic composition of claim 5 wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy are branched chains.
Claim 10
Dependent Claim
39 words
The therapeutic composition of claim 5 wherein said alkyl group and the alkyl moieties in alkoxy and alkylcarboxy are selected from the group consisting of methyl, ethyl, normal-propyl, isopropyl, normal-butyl, isobutyl, secondary- and tertiary-butyl, normal-amyl, isoamyl, secondary- and tertiary-amyl.
Claim 11
Dependent Claim
22 words
A method of inhibiting lipolysis in a mammal by administering to said mammal an effective amount of a composition of claim 8.
Claim 12
Dependent Claim
26 words
A method of treating ischemic heart disease and hypertriglyceridemia in a mammal by administering to said mammal an effective amount of a composition of claim 5.
Claim 13
Dependent Claim
2 words
6-Quinolyl-4-methoxy carbanilate.
Claim 14
Dependent Claim
2 words
6-Quinolyl-4-methoxy carbanilate.
Claim 15
Dependent Claim
2 words
5-Quinolyl-2-methoxy carbanilate.
Claim 16
Dependent Claim
2 words
5-Quinolyl-2-methoxy carbanilate.
Claim 17
Dependent Claim
2 words
7-Quinolyl-3-methoxy carbanilate.
Claim 18
Dependent Claim
2 words
7-Quinolyl-3-methoxy carbanilate.
Claim 19
Dependent Claim
2 words
7-Quinolyl-2-methyl carbanilate.
Claim 20
Dependent Claim
2 words
7-Quinolyl-2-methyl carbanilate.
Claim 21
Dependent Claim
2 words
7-Quinolyl-4-carbethoxy carbanilate.
Claim 22
Dependent Claim
2 words
7-Quinolyl-4-carbethoxy carbanilate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-10-14 | 1989-04-15 | 1989-10-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-10-14 | 1993-04-15 | 1993-10-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-10-14 | 1997-04-15 | 1997-10-15 | $7700.00 | Window Closed / Lapsed |